scholarly journals High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes

Radiology ◽  
2017 ◽  
Vol 285 (2) ◽  
pp. 472-481 ◽  
Author(s):  
Stephanie Nougaret ◽  
Yulia Lakhman ◽  
Mithat Gönen ◽  
Debra A. Goldman ◽  
Maura Miccò ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Outcomes ◽  
Brca Mutation ◽  
Ct Imaging ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Mutation Status

scholarly journals Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer

2018 ◽  
Vol 44 (6) ◽  
pp. 2040-2047 ◽  
Author(s):  
Andreas Meier ◽  
Harini Veeraraghavan ◽  
Stephanie Nougaret ◽  
Yulia Lakhman ◽  
Ramon Sosa ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Tumor Heterogeneity ◽  
Brca Mutation ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Mutation Status

Association of fusion genes with clinical outcomes and survival in high-grade serous ovarian cancer

2020 ◽  
Vol 159 ◽  
pp. 103-104
Author(s):  
A.M. Newtson ◽  
H.D. Reyes ◽  
Y.A. Lyons ◽  
N.D. Cardillo ◽  
D. Russo ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Outcomes ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Fusion Genes

scholarly journals Association between Morphologic CT Imaging Traits and Prognostically Relevant Gene Signatures in Women with High-Grade Serous Ovarian Cancer: A Hypothesis-generating Study

Radiology ◽  
2015 ◽  
Vol 274 (3) ◽  
pp. 742-751 ◽  
Author(s):  
Hebert Alberto Vargas ◽  
Maura Miccò ◽  
Seong Im Hong ◽  
Debra A. Goldman ◽  
Fanny Dao ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Ct Imaging ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Gene Signatures ◽  
Relevant Gene

scholarly journals Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer

2017 ◽  
Vol 110 (3) ◽  
pp. 265-272 ◽  
Author(s):  
R Tyler Hillman ◽  
Gary B Chisholm ◽  
Karen H Lu ◽  
P Andrew Futreal
Keyword(s):  
Ovarian Cancer ◽  
Clinical Outcomes ◽  
Genomic Rearrangement ◽  
High Grade ◽  
Serous Ovarian Cancer

scholarly journals Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study

Biomedicines ◽  
2021 ◽  
Vol 9 (1) ◽  
pp. 55
Author(s):  
Francesco Plotti ◽  
Corrado Terranova ◽  
Federica Guzzo ◽  
Carlo De Cicco Nardone ◽  
Daniela Luvero ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Brca Mutation ◽  
Predictive Marker ◽  
Chemotherapy Response ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Wild Type ◽  
Platinum Sensitive ◽  
Platinum Resistant

Even though 80% of patients with High-Grade Serous Ovarian Cancer respond to standard first-line chemotherapy, a majority of them could relapse in the following five years due to a resistance to platinum. Human Epididymis protein 4 (HE4) is one of the most promising markers in predicting platinum therapy response. This pilot study aims to evaluate the potential role of HE4 value in predicting chemotherapy response in BRCA mutated patients and in BRCA wild-type (non-mutated) ones. We selected 69 patients, affected by High-Grade Serous Ovarian Cancer, and optimally debulked and submitted to standard chemotherapy protocols. HE4 was dosed during every chemotherapy course. Patients were classified as platinum-resistant and platinum-sensitive. According to BRCA mutation test, patients were further divided into BRCA wild-type (53 patients), and BRCA mutated (16 patients). 35 patients out of 69 (52%) were platinum-sensitive (recurrence > 12 months), while 33 patients (48%) were platinum-resistant (recurrence < 12 months). Thus, in the total population, HE4 performed as a marker of chemosensitivity with a sensibility of 79% and a specificity of 97%. In the BRCA WT group, 23 patients out of 53 (43%) were platinum-sensitive, while 30 patients out of 53 (57%) were platinum-resistant. In the BRCA WT group, HE4 performed as a predictive marker of chemosensitivity with a sensibility of 80% and a specificity of 100%. In the BRCA mutated group, 13 patients out of 16 (82%) were platinum-sensitive, while 3 patients (18%) were platinum-resistant. In the BRCA mutated group, HE4 performed as a predictive marker of chemosensitivity in all patients. The ability to detect platinum-resistant patients before tumor relapse probably could open new therapeutic scenarios.

19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes

2018 ◽  
Vol 151 (2) ◽  
pp. 327-336 ◽  
Author(s):  
Diar Aziz ◽  
Dariush Etemadmoghadam ◽  
C. Elizabeth Caldon ◽  
George Au-Yeung ◽  
Niantao Deng ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Outcomes ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Cyclin E1

Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer

2019 ◽  
Vol 29 (2) ◽  
pp. 357-364 ◽  
Author(s):  
Jennifer Taylor Veneris ◽  
Lei Huang ◽  
Jane E Churpek ◽  
Suzanne D Conzen ◽  
Gini F Fleming
Keyword(s):  
Gene Expression ◽  
Ovarian Cancer ◽  
Overall Survival ◽  
Glucocorticoid Receptor ◽  
Cancer Patients ◽  
Brca Mutation ◽  
Receptor Expression ◽  
High Grade ◽  
Mutation Status ◽  
Relationship Of

ObjectiveHigh glucocorticoid receptor (GR) protein expression is associated with decreased progression-free survival in ovarian cancer patients and decreased sensitivity to chemotherapy in preclinical models. Prior studies suggest wild type BRCA1 promotes GR activation. The objective of this study was to characterize the relationship of tumor GR gene expression to outcome in ovarian cancer, and to evaluate the relationship of GR expression with BRCA status.MethodsWhole exome and whole genome sequencing, gene expression, and clinical data were obtained for high-grade serous ovarian cancers in The Cancer Genome Atlas. Cases with pathogenic somatic or germline BRCA1 or BRCA2 mutations were identified and classified as BRCA mutated. High or low glucocorticoid receptor expression was defined as expression above or below median of the GR/nuclear receptor subfamily 3 C1 (NR3C1) gene level. Overall survival was estimated by the Kaplan-Meier method and compared by Cox regression analysis.ResultsCombined germline DNA sequencing and tumor microarray expression data were available for 222 high-grade serous ovarian cancer cases. Among these, 47 had a deleterious germline and/or somatic mutation in BRCA1 or BRCA2. In multivariate analysis, high glucocorticoid receptor gene expression was associated with decreased overall survival among ovarian cancer patients, independently of BRCA mutation status. No correlation of GR/NR3C1 gene expression with BRCA mutation status or BRCA1 or BRCA2 mRNA level was observed.ConclusionsIncreased GR gene expression is associated with decreased overall survival in ovarian cancer patients, independently of BRCA mutation status. High-grade serous ovarian cancers with high GR expression and wild type BRCA have a particularly poor outcome.

Sign in / Sign up

Export Citation Format

Share Document